Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center.
about
Preexposure chemoprophylaxis for HIV prevention in men who have sex with menPreparing for HIV pre-exposure prophylaxis: lessons learned from post-exposure prophylaxisChoice of antiretroviral drugs for postexposure prophylaxis for adults and adolescents: a systematic reviewPractical guidance for nonoccupational postexposure prophylaxis to prevent HIV infection: an editorial reviewAntiretrovirals for primary HIV prevention: the current status of pre- and post-exposure prophylaxisHIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectivenessLimited Awareness and Low Immediate Uptake of Pre-Exposure Prophylaxis among Men Who Have Sex with Men Using an Internet Social Networking SiteAvailability of HIV postexposure prophylaxis services in Los Angeles CountyUptake and repeat use of postexposure prophylaxis in a community-based clinic in Los Angeles, California.Use of non-occupational post-exposure prophylaxis does not lead to an increase in high risk sex behaviors in men who have sex with men participating in the EXPLORE trialChemoprophylaxis for HIV prevention: new opportunities and new questions.Subsequent HIV infection among men who have sex with men who used non-occupational post-exposure prophylaxis at a Boston community health center: 1997-2013A randomized noninferiority trial of standard versus enhanced risk reduction and adherence counseling for individuals receiving post-exposure prophylaxis following sexual exposures to HIVLongitudinal trends in HIV nonoccupational postexposure prophylaxis use at a Boston community health center between 1997 and 2013.Testing the waters: Ethical considerations for including PrEP in a phase IIb HIV vaccine efficacy trial.Antiretroviral medication for preventing HIV infection in nonoccupational settings.Evolution of Massachusetts physician attitudes, knowledge, and experience regarding the use of antiretrovirals for HIV prevention.Evaluation of tolerability with the co-formulation elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate for post-HIV exposure prophylaxis.Antiretrovirals to prevent HIV infection: pre- and postexposure prophylaxis.Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension.Antiretroviral agents used by HIV-uninfected persons for prevention: pre- and postexposure prophylaxis.Prevention of the sexual transmission of HIV-1: preparing for success.Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education.Periconception pre-exposure prophylaxis to prevent HIV transmission: benefits, risks, and challenges to implementation.HIV medical providers' perceptions of the use of antiretroviral therapy as nonoccupational postexposure prophylaxis in 2 major metropolitan areas.Adherence to post-exposure prophylaxis for non-forcible sexual exposure to HIV: a systematic review and meta-analysis.The Promise of Antiretrovirals for HIV Prevention.Post-exposure prophylaxis following sexual exposure to HIV: a seven-year retrospective analysis in a regional centre.A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens.Patient attrition between the emergency department and clinic among individuals presenting for HIV nonoccupational postexposure prophylaxis.Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence.Evaluating counseling outcome on adherence to prophylaxis and follow-up after sexual HIV-risk exposure: a randomized controlled trial.Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial).Suspected unexpected and other adverse reactions to antiretroviral drugs used as post-exposure prophylaxis of HIV infection - five-year experience from clinical practice.
P2860
Q24612082-A98BD97A-8490-4D6C-AC06-54CEF4891459Q26820865-E25ACC39-AE12-4332-94D7-106B79F3D5C3Q26851448-6977A2BE-7608-44B9-ABA4-135EF7DD3186Q26853055-A33FB79C-E09D-41DF-9D1A-08CC8FE07646Q28085433-E94FF5E4-AD83-45A2-8848-EC4BEFF28E94Q28474086-8CE81094-D3CE-487F-B008-AF223F0CC337Q28730884-746E8F4B-3177-412D-B059-BE33FA03E9B4Q34071050-5F8D7CD7-424C-435C-A775-B63499A13AC2Q34116802-C0FD1BCD-8606-4E42-A588-072C9DD664CEQ34152689-FAA186A6-6FCD-45FE-AAA3-3BA982F8F96DQ34786284-4509EA15-2B7C-4CCC-87AA-3EEE85357F74Q34802731-1CA8111B-7CCB-4234-8A18-3722172C3B18Q35031691-867DA272-6059-4510-9E61-DAFD987F1202Q35696557-FB9D6F45-A2AF-428A-9541-AE51778B4284Q35862766-2A58AF80-46C4-4B1F-8BBA-F056AA45E823Q36089481-E832C774-077B-4F1C-8CE2-23567AA3238EQ36204616-40FE26C5-7B4B-4BF6-BDBA-A53FDE7DD22FQ36205915-6C705616-1642-49DC-BB99-D4EBDECEF2AAQ36597028-FAFC2C1B-D469-48B6-969C-2F1F8DBC6208Q36783183-5CCB6107-63D7-47C0-B731-DE7EFF44E4CCQ36873010-2BD2704B-935A-49D1-A488-4EF632E461E2Q36975282-E9A9E76A-0C9D-4F3D-8168-DA137BDEC704Q37137347-6EF862A6-20D6-4FAE-B08B-799B5AE97087Q37172505-0EB18848-4548-450E-99B5-A3ACD8362FB6Q37353723-C13DC08B-A441-44C3-B817-2825F378F858Q37395830-A6B161D0-7C24-4855-A438-1062E17D1C47Q37511883-EF8FF6C9-6208-4F7C-84B1-E65BBAE46EC4Q37850642-FEFC0904-8962-4804-BAF9-51C57FACF790Q39905748-4C1D0CB9-C215-47C9-8BAE-A4DBE7B8962BQ39905759-E03347FD-C4B7-4EF0-BF8E-4AFD4258985EQ40127599-FF38024E-6CA2-4B43-9049-1277F75CB01DQ42219760-1B4CA5E5-6606-4FA1-97B2-4E4522AE048EQ42248762-390C6222-FDDD-47E1-8AE6-EC6258B26F48Q43614773-5925DFAF-8148-4557-AE48-58301606DA15Q47830535-EB4D2BF7-CCDB-4937-A9AF-04C572B7459AQ55025502-5D40FFA5-35E2-4EE0-B54A-F986847E0E35
P2860
Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Tenofovir DF plus lamivudine o ...... oston Community Health Center.
@en
Tenofovir DF plus lamivudine o ...... ional postexposure prophylaxis
@nl
type
label
Tenofovir DF plus lamivudine o ...... oston Community Health Center.
@en
Tenofovir DF plus lamivudine o ...... ional postexposure prophylaxis
@nl
prefLabel
Tenofovir DF plus lamivudine o ...... oston Community Health Center.
@en
Tenofovir DF plus lamivudine o ...... ional postexposure prophylaxis
@nl
P2093
P1476
Tenofovir DF plus lamivudine o ...... oston Community Health Center.
@en
P2093
Alvan Fisher
Chris Grasso
Daniel Cohen
Rodney Van Derwarker
P304
P356
10.1097/QAI.0B013E318162AFCB
P407
P577
2008-04-01T00:00:00Z